Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Editas Medicine has received investment from 2 venture capital firms.
| Date | Round | Amount | Lead Investor |
|---|---|---|---|
| Feb 2026 | Series C+ | $180M | Flagship Pioneering |
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology.
Editas Medicine has received investment from Domain Associates, Third Rock Ventures. These venture capital firms and investors provide both capital and strategic support.
Editas Medicine operates in the Biotech sector. Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology.
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
